Nogitecan — Competitive Intelligence Brief

Nogitecan (topotecan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: topotecan. Area: Oncology.

marketed topotecan ATP-binding cassette sub-family G member 2 Oncology

Target snapshot

Nogitecan (topotecan) — Novartis. Topotecan is a topoisomerase inhibitor that prevents DNA re-ligation, causing double-strand DNA damage.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nogitecan TARGET	topotecan	Novartis	marketed	topotecan	ATP-binding cassette sub-family G member 2	1996-01-01
Cresemba	ISAVUCONAZONIUM	Astellas Pharma	marketed	Azole Antifungal	ATP-binding cassette sub-family G member 2	2015-01-01
Mycamine	MICAFUNGIN	Teva Pharms Usa Inc	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2005-01-01
Cancidas	CASPOFUNGIN	Merck & Co.	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2001-01-01
Protonix	pantoprazole	Generic (originally Byk Gulden/Altana/Nycomed)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1	2000-02-02
Kaletra	LOPINAVIR	Abbvie Deutschland Gmbh Co. Kg	marketed	Cytochrome P450 3A Inhibitor [EPC]	ATP-binding cassette sub-family G member 2	2000-01-01
Prevacid	lansoprazole	Generic (originally Takeda)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase	1995-05-10

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2036-04-21 — Prevacid · 11077055 · Formulation · US
• 2036-04-21 — Prevacid · 11986554 · Formulation · US

Sponsor landscape (topotecan class)

1. Novartis · 1 drug in this class